DK3685848T3 - Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension - Google Patents
Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension Download PDFInfo
- Publication number
- DK3685848T3 DK3685848T3 DK20150385.1T DK20150385T DK3685848T3 DK 3685848 T3 DK3685848 T3 DK 3685848T3 DK 20150385 T DK20150385 T DK 20150385T DK 3685848 T3 DK3685848 T3 DK 3685848T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- compositions
- treatment
- pulmonal
- hypertension
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907260P | 2013-11-21 | 2013-11-21 | |
| EP14864524.5A EP3071215B1 (en) | 2013-11-21 | 2014-11-21 | Compositions and methods for treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3685848T3 true DK3685848T3 (da) | 2021-12-13 |
Family
ID=53180397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20150385.1T DK3685848T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
| DK14864524.5T DK3071215T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14864524.5T DK3071215T3 (da) | 2013-11-21 | 2014-11-21 | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10682392B2 (da) |
| EP (3) | EP3071215B1 (da) |
| JP (3) | JP6640083B2 (da) |
| CN (1) | CN105934249A (da) |
| AU (3) | AU2014352843B2 (da) |
| CA (1) | CA2931309C (da) |
| DK (2) | DK3685848T3 (da) |
| ES (2) | ES2778201T3 (da) |
| WO (1) | WO2015077540A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116655801A (zh) | 2013-08-22 | 2023-08-29 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| EP3071215B1 (en) * | 2013-11-21 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| US20170202918A1 (en) | 2014-08-01 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
| EP3344660A4 (en) * | 2015-08-31 | 2019-07-03 | National Research Council of Canada | TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF |
| EP3496739B1 (en) | 2016-07-15 | 2021-04-28 | Acceleron Pharma Inc. | Compositions comprising actriia polypeptides for use in treating pulmonary hypertension |
| US10906957B2 (en) | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| IL305536A (en) | 2017-03-02 | 2023-10-01 | Nat Res Council Canada | TGF–B receptor ectodomain fusion compounds and their uses |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| BR112019023184A2 (pt) | 2017-05-12 | 2020-05-19 | Jiangsu Hengrui Medicine Co | proteína de fusão contendo o receptor de tgf-¿ e o uso farmacêutico da mesma |
| CN111511769A (zh) | 2017-09-27 | 2020-08-07 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| BR112020017382A2 (pt) | 2018-03-09 | 2021-01-26 | Agenus Inc. | anticorpos anti-cd73 e métodos de uso dos mesmos |
| CN111867612A (zh) * | 2018-03-26 | 2020-10-30 | 阿尔托生物科学有限责任公司 | 抗PDL1、IL-15和TGF-β受体组合分子 |
| TWI829799B (zh) | 2018-11-09 | 2024-01-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種TGF-β受體融合蛋白醫藥組成物及其用途 |
| WO2021021528A1 (en) * | 2019-07-26 | 2021-02-04 | Board Of Trustees Of Michigan State University | Methods of preventing or treating fatty degeneration of skeletal muscle |
| US20210061871A1 (en) * | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified N-810 and Methods Therefor |
| WO2021093760A1 (zh) * | 2019-11-12 | 2021-05-20 | 江苏恒瑞医药股份有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| WO2023206188A1 (en) * | 2022-04-28 | 2023-11-02 | Wenzhou Prarucom Bio-Chemical Technology Co. | Method for alleviating pulmonary fibrosis using epidermal growth factor |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EE9900492A (et) * | 1997-04-18 | 2000-06-15 | Biogen, Incorporated | II tüüpi TGF-ß retseptori/immunoglobuliini konstantse piirkonna hübriidvalgud |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| EP1087998A1 (en) | 1998-06-16 | 2001-04-04 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| JP2006502906A (ja) * | 2002-10-14 | 2006-01-26 | ソシエテ ド テクノロジー ミシュラン | 対称的な荷重分布を有するビードを備えた長期移動性タイヤ |
| EP1646655A2 (en) * | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| GB0514259D0 (en) | 2005-07-12 | 2005-08-17 | Renovo Ltd | Pharmaceutical compositions |
| WO2007108992A2 (en) | 2006-03-13 | 2007-09-27 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| EP2029625A2 (en) | 2006-06-05 | 2009-03-04 | Novartis AG | Use of tgf-beta antagonists in treatment of parathyroid-related disorders |
| CN100588717C (zh) | 2007-03-21 | 2010-02-10 | 中国医学科学院阜外心血管病医院 | 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途 |
| KR101171488B1 (ko) | 2007-08-22 | 2012-08-07 | 아이알엠 엘엘씨 | 키나제 억제제로서의 2-헤테로아릴아미노-피리미딘 유도체 |
| EP2037275A1 (en) | 2007-09-11 | 2009-03-18 | F. Hoffmann-La Roche AG | Differentiation of different causes of right heart failure |
| WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
| KR101008385B1 (ko) | 2008-08-01 | 2011-01-14 | 한국과학기술연구원 | 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법 |
| US20110172296A1 (en) | 2010-01-12 | 2011-07-14 | Bennett C Frank | Modulation of transforming growth factor-beta 1 expression |
| EP2372364A1 (en) | 2010-03-31 | 2011-10-05 | Medizinische Hochschule Hannover | Biomarker for pulmonary hypertension |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
| US9150651B2 (en) * | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
| DK2699590T3 (da) | 2011-04-20 | 2019-05-06 | Acceleron Pharma Inc | Endoglinpolypeptider og anvendelser deraf |
| KR102577578B1 (ko) | 2011-06-03 | 2023-09-11 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| CN104011069A (zh) | 2011-08-01 | 2014-08-27 | 塔夫茨医学中心有限公司 | 心力衰竭及相关病症的治疗 |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| WO2013059879A1 (en) | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| WO2013188787A1 (en) | 2012-06-15 | 2013-12-19 | The General Hospital Corporation | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF |
| EP2597466A1 (en) | 2012-06-26 | 2013-05-29 | Roche Diagniostics GmbH | Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients |
| EP2900263B1 (en) | 2012-09-26 | 2019-06-05 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| EP3689370A1 (en) | 2012-12-21 | 2020-08-05 | Aveo Pharmaceuticals Inc. | Anti-gdf15 antibodies |
| US10369198B2 (en) | 2013-01-17 | 2019-08-06 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| KR101346181B1 (ko) | 2013-02-18 | 2014-01-03 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12 |
| KR101346132B1 (ko) | 2013-02-18 | 2013-12-31 | 강원대학교산학협력단 | Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14 |
| CN116655801A (zh) | 2013-08-22 | 2023-08-29 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| EP3071215B1 (en) * | 2013-11-21 | 2020-01-08 | The Brigham and Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| ES2929725T3 (es) | 2014-05-18 | 2022-12-01 | Childrens Medical Center | Métodos y composiciones relacionadas con exosomas |
| MX2016016414A (es) | 2014-06-13 | 2017-04-10 | Novartis Ag | Uso de serelaxina para reducir gdf-15. |
| US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| US20170202918A1 (en) * | 2014-08-01 | 2017-07-20 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| CA2994413A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma, Inc. | Methods for treating myeloproliferative disorders |
-
2014
- 2014-11-21 EP EP14864524.5A patent/EP3071215B1/en active Active
- 2014-11-21 ES ES14864524T patent/ES2778201T3/es active Active
- 2014-11-21 CN CN201480073820.1A patent/CN105934249A/zh active Pending
- 2014-11-21 US US15/037,852 patent/US10682392B2/en active Active
- 2014-11-21 AU AU2014352843A patent/AU2014352843B2/en active Active
- 2014-11-21 JP JP2016533067A patent/JP6640083B2/ja active Active
- 2014-11-21 WO PCT/US2014/066776 patent/WO2015077540A2/en active Application Filing
- 2014-11-21 CA CA2931309A patent/CA2931309C/en active Active
- 2014-11-21 EP EP21190858.7A patent/EP4005585B1/en active Active
- 2014-11-21 DK DK20150385.1T patent/DK3685848T3/da active
- 2014-11-21 EP EP20150385.1A patent/EP3685848B1/en active Active
- 2014-11-21 ES ES20150385T patent/ES2902533T3/es active Active
- 2014-11-21 DK DK14864524.5T patent/DK3071215T3/da active
-
2019
- 2019-12-25 JP JP2019233811A patent/JP6952100B2/ja active Active
-
2020
- 2020-04-17 US US16/851,287 patent/US11951156B2/en active Active
- 2020-05-12 AU AU2020203110A patent/AU2020203110A1/en not_active Abandoned
-
2021
- 2021-09-27 JP JP2021156343A patent/JP7474729B2/ja active Active
-
2023
- 2023-11-12 AU AU2023263573A patent/AU2023263573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6952100B2 (ja) | 2021-10-20 |
| AU2014352843A1 (en) | 2016-06-16 |
| JP7474729B2 (ja) | 2024-04-25 |
| US20160287664A1 (en) | 2016-10-06 |
| AU2014352843B2 (en) | 2020-03-05 |
| EP3685848B1 (en) | 2021-09-15 |
| EP3071215B1 (en) | 2020-01-08 |
| EP3071215A2 (en) | 2016-09-28 |
| US20200323955A1 (en) | 2020-10-15 |
| JP6640083B2 (ja) | 2020-02-05 |
| ES2902533T3 (es) | 2022-03-28 |
| EP3685848A1 (en) | 2020-07-29 |
| AU2020203110A1 (en) | 2020-06-11 |
| US10682392B2 (en) | 2020-06-16 |
| CA2931309C (en) | 2022-06-21 |
| JP2020073528A (ja) | 2020-05-14 |
| CA2931309A1 (en) | 2015-05-28 |
| US11951156B2 (en) | 2024-04-09 |
| EP4005585A1 (en) | 2022-06-01 |
| JP2017501977A (ja) | 2017-01-19 |
| ES2778201T3 (es) | 2020-08-10 |
| EP4005585B1 (en) | 2024-03-27 |
| AU2023263573A1 (en) | 2023-11-30 |
| CN105934249A (zh) | 2016-09-07 |
| WO2015077540A2 (en) | 2015-05-28 |
| EP3071215A4 (en) | 2017-08-23 |
| WO2015077540A3 (en) | 2015-11-19 |
| DK3071215T3 (da) | 2020-03-23 |
| JP2021193139A (ja) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3685848T3 (da) | Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
| DK3008168T3 (da) | Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3556869T3 (da) | Sammensætninger og fremgangsmåder til sekventering af polynukleotider | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK2970890T3 (da) | Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3238707T3 (da) | Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet | |
| DK3363805T3 (da) | Fremgangsmåder til syntese af sphingomyeliner og dihydrosphingomyeliner | |
| DK2967049T3 (da) | Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme | |
| DK2994533T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3089707T3 (da) | Vævtransplantater og fremgangsmåder til fremstilling og brug af samme | |
| DK3077513T3 (da) | Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande |